Enveric Biosciences

ENVB

Market cap $6.08M

ENVB Hedge Fund Activity: Q1 2026 in Review

11 of the 8,161 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q1 2026, worth a combined $107K — up 21% from $87.7K a quarter earlier.

Fund positioning in ENVB was balanced in Q1 2026: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $87.7K. The largest seller was Citigroup, exiting entirely with an estimated $8.26K sold.

• 11 institutional investors held Enveric Biosciences (ENVB) as of Q1 2026, unchanged from Q4 2025.
• Funds reported $107K of Enveric Biosciences stock for Q1 2026, up 21% quarter-over-quarter.
• 2 funds opened new Enveric Biosciences positions in Q1 2026 and 2 closed out, a net change of 0 holders.
• The largest Enveric Biosciences buyer in Q1 2026 was Geode Capital Management, an estimated $87.7K added.
• The largest Enveric Biosciences seller in Q1 2026 was Citigroup, an estimated $8.26K sold.

Based on aggregated 13F filings for Q1 2026.